Delving into the Latest Updates on 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine

Synonyms

PCV13

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Pneumococcal Infections

Inactive Indication-

Originator Organization

Beijing Kexing Zhongwei Biotechnology Co. Ltd.

Active Organization

Beijing Kexing Zhongwei Biotechnology Co. Ltd.

Sinovac Biotech Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseNDA/BLA

First Approval Date-

Regulation-

Login to view timeline

A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.

Start Date01 May 2026

Sponsor / Collaborator

Beijing Kexing Zhongwei Biotechnology Co. Ltd.

CTR20233341

/ Active, not recruitingPhase 3

评价13价肺炎球菌多糖结合疫苗在2月龄（最小6周龄）~5岁（6岁生日前）健康婴幼儿的免疫原性和安全性的随机、盲法、阳性对照Ⅲ期临床试验

[Translation] A randomized, blinded, positive-controlled phase III clinical trial to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy infants aged 2 months (minimum 6 weeks) to 5 years (before the 6th birthday)

评价科兴中维PCV13的免疫原性和安全性。

[Translation]

To evaluate the immunogenicity and safety of Sinovac PCV13.

Start Date23 Oct 2024

Sponsor / Collaborator

Sinovac Biotech Co., Ltd.

[+1]

NCT06183216

/ CompletedPhase 1

A Randomized, Double Blinded, Positive Controlled Phase Ⅰb Clinical Trial in Participants Aged 2 Months (42-89 Days) and 2 to 5 Years to Evaluate the Safety and Immunogenicity of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.

Start Date04 Jan 2024

Sponsor / Collaborator

Sinovac Research And Development Co Ltd

100 Clinical Results associated with 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences)

Login to view more data

100 Translational Medicine associated with 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences)

Login to view more data

100 Patents (Medical) associated with 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences)

Login to view more data

100 Deals associated with 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumococcal Infections	Phase 3	China	Beijing Kexing Zhongwei Biotechnology Co. Ltd.	23 Oct 2024
Pneumococcal Infections	Phase 3	China	Sinovac Biotech Co., Ltd.	23 Oct 2024